A European pre-market clinical trial is typically. Hence, the device risk class. The cost isn’t one number; it’s a stack of categories, several of which are EU-specific and easy to underestimate. Below is the full breakdown, typical ranges by study type, and the drivers that move the figure most. We also have a budgeting tool to model yours.
Planning a trial in Europe means budgeting against real regulatory and operational complexity, not just setting funds aside. Under the EU Medical Device Regulation (MDR 2017/745), clinical investigations are mandatory for high-risk devices (Class III and some Class IIb), and each country runs its own approval process, so timelines and costs multiply with every border you cross. Sponsors must secure both Competent Authority and Ethics Committee approvals, and appoint an EU legal representative even when working with a CRO.
What cost categories make up the budget?
Breaking costs into clear categories increases transparency for sponsors and investors and stops significant expenses slipping through unnoticed.
Regulatory & start-up. MDR submissions and translations into each country’s local language; ethics committee fees (charged in almost all EU countries); site contracts, GDPR compliance, and EU representative fees; preparation of the protocol, Investigator’s Brochure (IB), and device dossier.
CRO project management. A central project manager for overall coordination; country-specific clinical leads for local execution; CRO overhead, often calculated per site per month.
Site & patient costs. Site start-up of €5,000–€7,000 per site (contracts and staff training); patient reimbursement of €2,000–€5,000 depending on procedure complexity; investigator meetings and training; follow-up visits, with long-term follow-up increasingly required under MDR.
Monitoring & clinical operations. On-site monitoring at €1,500–€2,000 per CRA visit; travel at €350–€500, depending on location; remote monitoring options are often more cost-efficient.
Device supply & logistics. CE-mark investigational labeling in multiple languages; distribution, warehousing, and returns across Europe; additional site tooling or kits where needed.
Data management & statistics. GDPR-compliant EDC system setup and licensing; eTMF and CTMS platforms with licensing fees; data cleaning and query management; biostatistics for interim analyses and the final Clinical Study Report (CSR).
Safety & medical monitoring. SAE reporting and vigilance as required by MDR; annual safety reports; Data Safety Monitoring Board (DSMB) oversight for high-risk devices.
Pass-through costs. Central labs or imaging core labs, where applicable; translation of all patient-facing materials; long-term archiving (MDR and GDPR require at least 10 years); patient insurance, mandatory and varying by country.
Contingency (10–20%). Protocol amendments and additional regulatory requests are common, so a 10–20% buffer protects the budget.
What does a trial cost by study type?
The final budget depends heavily on study size, complexity, number of countries, and length of follow-up.
Small feasibility study
50–100 patients, 4–8 sites in 1–2 countries, shorter-term follow-up. Typical budget: several hundred thousand euros.
Pivotal MDR trial
80–150 patients, 8–12 sites across 3–5 countries, 2–3 years of follow-up. Typical budget: 3 to 8 million euros.
Complex implantable/high-risk devices
Cardiology, orthopedics, or neurology devices, often involving imaging and extended follow-up, with intensive monitoring and DSMB oversight. Typical budget: 10 to 25+ million euros.
What EU-specific factors drive up the cost?
Beyond the universal categories, four EU-specific elements hit budgets directly: translations of regulatory documents and all patient materials; patient insurance, mandatory with rates varying by country; GDPR compliance, driving higher IT and data-protection costs; and multi-country submissions, each carrying separate Competent Authority and Ethics Committee fees.
Model your own budget
The fastest way to turn these ranges into a real number is to model your own study. Qserve CRO’s budgeting calculates and manages costs line by line, and if you plan to run certain parts of the trial in-house, you can remove them from the sheet so you only budget what you’re outsourcing.
Qserve CRO can support your trial fully or partially — from submissions and site coordination to patient recruitment, GDPR compliance, and cost-optimization — drawing on deep experience in multi-country EU trials. That flexibility means you can hand over the whole study or just the pieces you don’t want to staff yourself.
Ready to model your trial budget?
Please reach out to us to plan, budget, and execute your next trial efficiently and compliantly.
Couldn't find your question?
How long does a European pre-market clinical trial take?
Timelines depend on the number of countries and the follow-up period. Each country’s Competent Authority and Ethics Committee review runs on its own schedule, and approvals can’t be fully parallelized, so a multi-country pivotal trial with two to three years of follow-up will run substantially longer than a single-country feasibility study, typically taking 3 to 5 years from initial regulatory submission to final data lock.
Can I run part of the trial in-house to reduce costs?
Yes. Our budgeting tool lets you remove any line you intend to handle yourself, so you only pay for the scope you outsource. Sponsors commonly keep tasks like patient recruitment or certain monitoring activities internal while outsourcing regulatory submissions and country coordination.
Do I need a clinical trial for a Class IIb device?
Sometimes. Under MDR, clinical investigations are mandatory for Class III and some Class IIb devices. Whether yours falls into that subset depends on the device, its claims, and the available clinical evidence. A clinical strategy assessment is the way to confirm before you budget.
What is the minimum budget contingency I should plan for?
Plan for 10–20%. Protocol amendments and additional regulatory requests are common across multi-country EU trials, and a contingency in that range protects the budget without overstating it.